Skip to content
Oxcia

Oxcia

  • About us
    • About us
    • Management
    • Board
    • Scientific Advisory Board
    • Collaborators
    • Partnerships
    • History
    • Careers
  • Scientific Platform
    • Scientific Platform
    • Glossary
  • Pipeline
    • Pipeline
    • OXC-101
    • OXC-201
  • Investors
    • Investors
    • Governance
    • Ownership structure
    • Financial reports
    • Presentations
    • Upcoming events
    • Investor contact
  • Investerare
    • Investerare
    • Bolagsstyrning
    • Extra Bolagsstämma 4 juni 2025
    • Ägarstruktur
    • Finansiella rapporter
    • Pressmeddelanden
    • Presentationer
    • Kalender
    • Investerarkontakt
  • News and Press
  • Contact
  • Search

Home › News and Press › Press releases

News and Press releases

View all News Press releases

Oxcia AB Publishes Year-End Report for 2024

February 21, 2025 · Press releases
Read article

OXC-101 has been granted ODD status by the FDA in AML

February 20, 2025 · Press releases
Read article

Oxcia appoints Eva Sjökvist Saers as Chairman of the Board

February 5, 2025 · Press releases
Read article

Data presented for OXC-101 for a new indication – psoriasis

January 29, 2025 · Press releases
Read article

Professor Helleday presents new data on OXC-101 for psoriasis

January 23, 2025 · Press releases
Read article

Oxcia AB (publ) publishes interim report for the third quarter 2024

November 22, 2024 · Press releases
Read article

Oxcia is focusing the development of OXC-101 on hematological cancers

October 4, 2024 · Press releases
Read article

Oxcia presents OXC-201 at ICLAF 2024

September 4, 2024 · Press releases
Read article

New publications in peer-reviewed scientific journals support the potential for OXC-101 as a novel anti-cancer therapy

June 11, 2024 · Press releases
Read article

Patent approval now also secured in the US, the largest IPF market

May 17, 2024 · Press releases
Read article

Another key milestone for OXC-201 – patent approval in China

May 3, 2024 · Press releases
Read article

Key milestone for OXC-101 – study approval in South Africa

March 21, 2024 · Press releases
Read article
« Back 1 2 3 Forward »

Contact us

Oxcia AB
Norrbackagatan 70C
113 34 Stockholm, Sweden

+46 (0)73 270 96 05

info@oxcia.com

Privacy policy

Menu

  • About us
    • About us
    • Management
    • Board
    • Scientific Advisory Board
    • Collaborators
    • Partnerships
    • History
    • Careers
  • Scientific Platform
    • Scientific Platform
    • Glossary
  • Pipeline
    • Pipeline
    • OXC-101
    • OXC-201
  • Investors
    • Investors
    • Governance
    • Ownership structure
    • Financial reports
    • Presentations
    • Upcoming events
    • Investor contact
  • Investerare
    • Investerare
    • Bolagsstyrning
    • Extra Bolagsstämma 4 juni 2025
    • Ägarstruktur
    • Finansiella rapporter
    • Pressmeddelanden
    • Presentationer
    • Kalender
    • Investerarkontakt
  • News and Press
  • Contact
  • Search

Social media

  • Linkedin

OXC-201

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the European Innovation Council can be held responsible for them.


an EIC project aiming to bring hope to IPF patients

© Copyright Oxcia 2025 · Legal Notice · Information About Cookies

Search

More results

Generic filters